|Day Low/High||85.33 / 87.27|
|52 Wk Low/High||62.66 / 94.98|
I like cheap smaller caps with little to no exposure to the global economy.
A breakdown below $52 should be the tipping point for further declines in ABBV.
If I had to guess, today's sharp rally was a function of monthly inflows, technical breakouts and programs. But it is only a guess. However, you will watch in the business media all the talking heads who liked yesterday's market and purchased opport...
Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.
I started the day giving my bona fide and unadulterated and honest view of Berkshire Hathaway (BRK.B) in a two-part opening missive, which is here and here. Today, for a change, an inside day bereft of much volatility. Oops, wait. Not so much now i...
Some names should do well regardless of who becomes the next president.
Some stocks should do well regardless of who is the next president.
I am not ready to go full "risk on," but it's nice to see the market out of its cage.
The electrics have been crackling, but the group has more downside risk than currently perceived.
They offer impressive free cash flow, great balance sheets, evolving pipelines and nice dividend yields.
The market's major indices are getting worse as the morning progresses. There are deep losses across the board, with the Nasdaq Composite down nearly 3% at last check. Maybe we'll get some relief from the European markets closing. Oil is holding its...
In a year's time, investors may look back and think this was a great entry point.
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.
The year has not started the way most pundits and prognosticators had envisioned.
It was all about the FANGs in 2015, but go for value plays this year.
Ireland’s Shire has clinched Baxalta with a stock and cash deal worth $32 billion on Monday.
Look for market leadership to shift as the U.S. economy plods along.
5 biotech stocks that could outperform the overall market in 2016.
United Kingdom-based AstraZeneca agreed to acquire a 55% stake in Dutch Acerta Pharma in a $4 billion deal, the company announced on Thursday.
The merged company can become multiple companies.
History indicates pharmaceutical companies with low multiples offer payoffs down the road.
Look for 2015's record run of mergers and acquisitions to continue.